Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasmsValerio De Stefano, Tiziano Barbui, Juan Carlos Hernández‐Boluda et al.|Blood Cancer Journal|2018Cited by 38
SARS-CoV-2 infection and acute ischemic stroke in Lombardy, ItalyAlessandro Pezzini, Mario Grassi, Giorgio Silvestrelli et al.|Journal of Neurology|2021Cited by 12
Combining Intravenous Thrombolysis and Dual Antiplatelet Treatment in Patients With Minor Ischemic Stroke: A Propensity Matched Analysis of the READAPT Study CohortRaffaele Ornello, Simone Beretta, Matteo Foschi et al.|Journal of the American Heart Association|2024Cited by 12
Exploring Sex Differences in Outcomes of Dual Antiplatelet Therapy for Patients With Noncardioembolic Mild-to-Moderate Ischemic Stroke or High-Risk Transient Ischemic Attack: A Propensity-Matched Analysis of the READAPT Study CohortMatteo Foschi, Daniele Orsucci, Lucio D’Anna et al.|Stroke|2024Cited by 5
Admission systolic blood pressure and short-term outcomes after dual antiplatelet therapy in patients with minor ischemic stroke or transient ischemic attackFederico De Santis, Roberto Tarletti, Eleonora De Matteis et al.|Therapeutic Advances in Neurological Disorders|2025Cited by 1